Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2007
Date:2/19/2008

Purchases of intangible fixed assets (357) (1,400)

Interest received 1,406 14

Net cash used in investing activities (296) (1,773)

Cash flow from financing activities

Proceeds from issuance of loans - 1,700

Redemption of loans (1,613) (1,700)

Capital contribution shareholders 51,361 -

Proceeds from issuance of preference - 21,821

shares

Net cash generated from financing 49,748 21,821

activities

Net (decrease)/ increase in cash,

cash equivalents

and bank overdrafts 37,272 13,537

Cash, cash equivalents and bank

overdrafts

In the beginning of the year 14,058 521

Cash, cash equivalents at the end of 51,330 14,058

the year


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
4. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
5. Acrongenomics on Track to Acquire Molecular Vision
6. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
7. Acrongenomics Acquires Equity Stake in Molecular Vision
8. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
9. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
10. Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth
11. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... Knowledgent , the data and analytics firm, today ... utilizing data lakes in the healthcare industry. , As the Internet of Things (IoT) ... over the last few years as more entities become technology enabled through Electronic Medical ...
(Date:9/1/2015)... ... 2015 , ... Research conducted by Synedgen Inc.’s Director for ... of Medicine, Frederick National Laboratory for Cancer Research, and the Centers for Disease ... journal. , Christopher Ryan PhD, of Synedgen, and Aparajita Chatterjee, Daniel M. ...
(Date:8/31/2015)... 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... orders are for air emission abatement projects in ... a large order for a municipality in the ... a competitor,s system that failed to meet the customer,s requirements. This ... said Derek S. Webb , President and Chief Executive ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Mexico Biomedical Sensors Market - Growth, Trends & ... The Mexico Biomedical Sensors market is estimated ... 2.68% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Mexico Biomedical Sensors Market Report 2015-2020 2
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2